Table 2.
Other indications of sarilumab beyond RA
| Phase | Study number | Status | Condition | Study description |
|---|---|---|---|---|
| – | NCT03378219 | Not yet recruiting | RA | An observational study on sarilumab-exposed pregnancies |
| Phase I | NCT03679845 | Not yet recruiting | Morphea, plaque form | Study to assess sarilumab in halting progression of morphea |
| Phase II | NCT02776735 | Recruiting | JIA | An open-label, ascending, repeated dose-finding study of sarilumab in children and adolescents with polyarticular-course JIA |
| NCT02991469 | Recruiting | JIA | A repeated dose-finding study of sarilumab in children and adolescents with systemic JIA | |
| NCT01764997 | Terminated | AS | Extension study for long term evaluation of sarilumab in patients with AS | |
| NCT03770273 | Recruiting | Indolent systemic mastocytosis | Safety and efficacy of s.c. sarilumab in improving the quality of life in people with indolent systemic mastocytosis | |
| Phase III | NCT03600805 | Recruiting | GCA | Evaluation of efficacy and safety of sarilumab in patients with GCA |
| NCT03600818 | Recruiting | PMR | Evaluation of the efficacy and safety of sarilumab in patients with PMR |
Abbreviations: RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; AS, ankylosing spondylitis; GCA, Giant-Cell Arteritis; PMR, polymyalgia rheumatica.